Abstracts

ABSTRACTS

This is your opportunity to showcase your work – from clinical studies to basic translational science,
case reports, and epidemiological studies to thousands of colleagues.

Abstract submission is now open for ISID’s Congress 2022!

All abstracts for the Congress must be submitted electronically through the electronic abstract submission system.

  • All abstracts must be submitted in English.
  • All abstracts must be received on or before Monday, August 15, 2022 at 23:59 CET.
  • All abstracts have a 300 word limit of text (not including presenter information and title).
  • Abstracts must be based on original results that have not or will not be published or presented before the Congress begins on November 17, 2022.
  • Submitting authors are required to ensure that all listed co-authors have reviewed the abstract, take responsibility for its content, and agree with being listed as a co-author.
  • All potential conflicts of interest for each co-author must be provided. Potential conflicts of interest include but are not limited to, commercial interest in the research and financial or in-kind support for the research from entities with a commercial interest in the research.
  • Abstract acceptance notifications will be sent by September 1, 2022.
  • Only the highest-scoring accepted abstracts will be published as an online supplement to the International Journal of Infectious Diseases (IJID)

Additional Information

  • We expect that more than 900 abstracts will be presented during the Congress. Eighty reviewers from more than 30 countries are reviewing and scoring abstracts. The abstract review process is blinded, meaning that authors’ names and affiliations are not disclosed to reviewers.
  • Each abstract will be reviewed and scored by two reviewers for the quality and originality of the research, the scientific content, and the presentation. A notice of acceptance or rejection will be sent to the submitting authors only. It is the responsibility of the submitting author to notify other co-authors of the Committee’s decision. Session assignments will be mailed by October 15, 2022 to the address given for correspondence.
  • Acceptance of the abstract in the program and assignment to a session are determined solely by the Program Committee based on the abstract’s subject matter and combined reviewer scores and comments. Decisions of the Program Committee are final. Because of the logistics of assigning abstracts to sessions and the number of abstracts received, requests for particular types of presentations, sessions, days, or times will not be considered by the Program Committee.
  • Presenters of accepted abstracts must be registered and attend the Congress in order to have the abstract published in the online supplement to the International Journal of Infectious Diseases (IJID).
  • By submitting an abstract the author(s) agree to transfer all copyrights to ISID and to allow publication of submitted information on the ISID website, the International Journal of Infectious Diseases (IJID), or other Society related publications.
  • Instructions will be sent to the authors whose abstracts are accepted for oral or poster presentations. For each abstract accepted for presentation, at least one author must attend the Congress and present the contribution.
  • If the registration fee of the presenting author is not received by October 1, 2022 the abstract will not be published in the Final Program.
  • By submitting an abstract the author(s) agree to transfer all copyrights to ISID and to allow publication of submitted information on the ISID website, the International Journal of Infectious Diseases (IJID), or other Society related publications.

The Congress Program Committees invite submission of abstracts of excellent quality in all areas related to infectious diseases as detailed below:

Animal Models, Pathogenesis and Host Defenses
Antimicrobial Adverse Events
Antimicrobial Resistance
Antimicrobials: Antimicrobial Stewardship
Antimicrobials: Clinical Trials
Antimicrobials: Mechanisms and Spectrum
Antimicrobials: Pharmacology, PK/PD
Bacterial Infections
Big Data, Genomics and Infectious Diseases
Climate change and ecological factors in infectious diseases
Clinical Case Report/Series
COVID-19 Pathogenesis
COVID-19 Diagnostics and Therapeutics
COVID-19 Vaccines
COVID-19 Infection Prevention and Control
COVID-19 Big Data, Surveillance and Contact tracing
COVID-19 Ethics and Misinformation
Device-related infections
Diagnostics & Molecular Technologies
Digital Health & Innovation
Economics, Health Policy and Implementation
Education Advancements in One Health
Emerging & Re-emerging Infectious Diseases
Ethical Issues in Infectious Diseases
Foodborne and Waterborne Diseases
Healthcare Associated Infections & Critical Care
HIV/AIDS and Other Retroviruses
Immunocompromised Hosts (non-HIV)
Infection Prevention & Control
Infections Related to Travel and Migration
Infections in Displaced Populations, Refugees and Migrants
Infectious Diseases challenges in low income settings
Infectious Diseases and Artificial Intelligence
Infectious Diseases and Digital Health
Infectious Disease Surveillance & Notification
Influenza and Other Respiratory Infections (non COVID-19)
Helminth Infections
Mycology, Fungal Infections & Antifungal Drugs
New Pathogen Discovery
Nosocomial Infections
Outbreak Modeling and Forecasting
Outbreak Preparedness
Outbreak Response and Control
Political Factors in Disease Emergence and Response
Public Communication of Outbreaks and Emerging Diseases
Rumors and Misinformation in Infectious Diseases
One Health
Parasitology and Parasitic Infections
Pediatric and Perinatal Infections
Sexually Transmitted Diseases
Social Inequalities and Access Inequalities
Travel Medicine & Travel Health
Tuberculosis & Other Mycobacterial Infections
Tuberculosis and treatment resistance
Vaccines and Vaccine Development
Vector Borne Diseases and Vector Control
Viral Hepatitis
Virology & Viral Infections (non-HIV)
Zoonoses & Infections in Animals
Other

Abstracts may be accepted into one of three categories:

  • Oral Presentation

Highest scoring abstracts will be selected for oral presentations. The presenting author will be required to make a 7-minute PowerPoint presentation that concisely summarizes the research question, methods used, the results, and their significance. Abstracts accepted for oral presentation will be published as an online supplement to the International Journal of Infectious Diseases.

  • Poster Presentation

The presenting author will be obliged to present the poster during the moderated poster session in Kuala Lumpur to which it has been assigned. The highest-scoring abstracts accepted for poster presentation will be published as an online supplement to the International Journal of Infectious Diseases (IJID).

  • ePoster Presentation

Abstracts accepted into this category will be available for viewing and discussion on computer terminals at the Congress and online. The highest-scoring abstracts accepted for electronic poster presentation will be published as an online supplement to the International Journal of Infectious Diseases (IJID).

Presenters who do not attend the session for which they have been scheduled will be ineligible to submit an abstract for the next Congress. Those abstracts will not be published in the International Journal of Infectious Diseases.

Research Abstracts 

Research abstracts should follow the format below:

  • Background: A statement of the hypothesis or research question.
  • Methods & Materials: An explanation of the study design and experimental method and materials used.
  • Results: A concise summary of the major findings of the experiment or study. Sufficient data must be provided to permit evaluation by the reviewers and public reading of the abstract. Statements such as “additional information to be presented at the meeting” are not acceptable.
  • Conclusion: Summary of the overall findings and the importance of the study.

Abstracts that represent the presentation of investigations of compounds that involve inadequate numbers of study subjects, in vitro studies of non-representative microbiologic strains, or abstracts that lack quantitative or qualitative data will not be accepted. Authors are discouraged from submitting multiple abstracts from the same project. Each abstract will be judged on its own merits without reference to other submissions. Repetitive abstracts will be rejected. There is no limit to the number of abstracts you can submit. However, an author may present no more than two abstracts. If more than two submissions are accepted from an author, one of his/her co-authors must present any additional abstracts. The presenter of any accepted abstract must be one of the co-authors listed on the original submission. Please note that authors may not submit the same research; abstracts containing identical or nearly identical data from the same institution and/or individuals will be rejected.

Clinical Case Reports 

A Case Report is a brief description of a particular condition that is unusual and also provides new insights into diagnosis or clinical management. A case report must make a distinct, novel contribution to the understanding of the etiologic agent, its clinical manifestations, and/or its diagnosis or treatment. 

Clinical case reports should follow the format below:

  • Background: A statement on the particular condition that is unusual.
  • Case Description: A description of key features of the case. Sufficient data must be provided to permit evaluation by the reviewers and public reading of the abstract.
  • Discussion: A concise discussion of the distinct, novel contribution of the case to the understanding of the disease, its clinical manifestations, and/or its diagnosis or treatment. 
  • Conclusion: Summary of the overall findings and the importance of the case report. 

Case reports must be authentic, understandable, educational, and clinically interesting to an international audience of healthcare professionals, researchers, and others in all infectious diseases subspecialties. Each case report will be judged on its own merits without reference to other submissions. Repetitive case reports will be rejected.

Should you require further explanation, please send an e-mail to [email protected].